pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.76 [0.58, 0.99]< 10%1 study (1/-)97.8 %NAnot evaluable crucial-
deaths (OS) (extension) 0.75 [0.59, 0.95]< 10%1 study (1/-)99.2 %NAnot evaluable important-
progression or deaths (PFS) 0.59 [0.47, 0.74]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 0.53 [0.33, 0.85]> 10%1 study (1/-)0.4 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 4.11 [0.46, 37.05]< 10%1 study (1/-)10.5 %NAnot evaluable non important-
AE (grade 3-4) 2.41 [1.64, 3.53]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 1.61 [0.95, 2.72]< 10%1 study (1/-)3.8 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 1.50 [0.75, 2.96]< 10%1 study (1/-)12.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.